Mobile Site ›

The Use of Genetics in Guiding Therapy

CYP2C19 PGx Testing for Clopidogrel

Slide 10

June 2012

CYP2C19 testing for predicting response to clopidogrel is currently performed clinically. However, the widespread adoption of this testing has not yet occurred and may be due, in part, to the lack of recommendation as per the 2011 guidelines by the American College of Cardiology and other clinical groups. Nonetheless, some would argue that there is sufficient evidence to provide this testing for certain groups of patients, such as those undergoing coronary stenting. It is anticipated that large, randomized, prospective clinical outcomes trials are likely needed before clinical adoption of this testing can be more fully embraced.

CYP2C19 PGx Testing for Clopidogrel


Jump to section: